Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

BACKGROUND: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in pretreated metastatic colorectal cancer (mCRC)...

Full description

Bibliographic Details
Main Authors: Abajo, A. (Ana), Rodriguez, J. (Javier), Bitarte, N. (Nerea), Zarate, R. (Ruth), Boni, V. (Valentina), Ponz-Sarvise, M. (Mariano), Chopitea, A. (Ana), Bandres, E. (Eva), Garcia-Foncillas, J. (Jesús)
Format: info:eu-repo/semantics/article
Language:eng
Published: Cancer Research UK 2014
Subjects:
Antibodies, Monoclonal
Bevacizumab
Irinotecan
Gemcitabine
Colorectal Neoplasms/pathology
Online Access:https://hdl.handle.net/10171/36370

Similar Items

Similar Items